Phase I safety study of ranolazine in pulmonary arterial hypertension

di Gomberg-Maitland, Mardi, Schilz, Robert, Mediratta, Anuj, Addetia, Karima, Coslet, Sandra, Thomeas, Vasiliki, Gillies, Hunter, Oudiz, Ronald J.
Pubblicato in Pulm Circ (2015)

Technical Considerations in the Development of Circulating Peptides as Pharmacodynamic Biomarkers for Angiogenesis Inhibitors

di Thomeas, Vasiliki, Chow, Selina, Gutierrez, Jose O., Karovic, Sanja, Wroblewski, Kristen, Kistner-Griffin, Emily, Karrison, Theodore G., Maitland, Michael. L.
Pubblicato in J Clin Pharmacol (2014)

Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies

di Karovic, Sanja, Wen, Yujia, Karrison, Theodore G., Bakris, George L., Levine, Matthew R., House, Larry K., Wu, Kehua, Thomeas, Vasiliki, Rudek, Michelle A., Wright, John J., Cohen, Ezra E.W., Fleming, Gini F., Ratain, Mark J., Maitland, Michael L.
Pubblicazione 2014

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of pazopanib

di Maitland, Michael L., Xu, Chun-Fang, Cheng, Yu-Ching, Kistner-Griffin, Emily, Ryan, Kathleen A., Karrison, Theodore G., Das, Soma, Torgerson, Dara, Gamazon, Eric, Thomeas, Vasiliki, Levine, Matthew R., Wilson, Paul A., Bing, Nan, Liu, Yuan, Cardon, Lon R., Pandite, Lini N., O’Connell, Jeffrey R., Cox, Nancy J., Mitchell, Braxton D., Ratain, Mark J., Shuldiner, Alan R.
Pubblicato in Clin Cancer Res (2014)